Relmada Therapeutics, Inc.
RLMD
$4.80
$0.051.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -30.89% | -8.50% | -6.49% | 53.55% | 44.47% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.80% | -1.84% | -38.93% | -52.26% | -51.73% |
| Change in Net Operating Assets | 3,349.00% | 95.82% | -64.82% | 90.98% | 100.95% |
| Cash from Operations | -50.06% | 16.60% | -65.87% | 59.64% | 51.73% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 163.31% | -980.40% | -778.07% | -58.17% | -52.35% |
| Cash from Investing | 163.31% | -980.40% | -778.07% | -58.17% | -52.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8,837.26% | -- | 100.00% | 100.00% | -- |
| Cash from Financing | -8,695.89% | -- | 54,382.78% | 100.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 665.23% | 331.96% | -11.00% | 105.16% | -72.90% |